

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

6-6-2023

Novel vaccine against pathological pyroglutamate-modified amyloid beta for prevention of Alzheimer's disease

Karen Zagorski
Institute for Molecular Medicine

Olga King
Institute for Molecular Medicine

Armine Hovakimyan
Institute for Molecular Medicine

Irina Petrushina
University of California, Irvine

Tatevik Antonyan
Institute for Molecular Medicine

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4



Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Recommended Citation

Zagorski, Karen; King, Olga; Hovakimyan, Armine; Petrushina, Irina; Antonyan, Tatevik; Chailyan, Gor; Ghazaryan, Manush; Hyrc, Krzysztof L; Chadarevian, Jean Paul; Davtyan, Hayk; Blurton-Jones, Mathew; Cribbs, David H; Agadjanyan, Michael G; and Ghochikyan, Anahit, "Novel vaccine against pathological pyroglutamate-modified amyloid beta for prevention of Alzheimer's disease." *International Journal of Molecular Sciences*. 24, 12. 9797 (2023).

https://digitalcommons.wustl.edu/oa_4/2069

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Karen Zagorski, Olga King, Armine Hovakimyan, Irina Petrushina, Tatevik Antonyan, Gor Chailyan, Manush Ghazaryan, Krzysztof L Hyrc, Jean Paul Chadarevian, Hayk Davtyan, Mathew Blurton-Jones, David H Cribbs, Michael G Agadjanyan, and Anahit Ghochikyan



Article

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer's Disease

Karen Zagorski ^{1,†}, Olga King ^{1,†}, Armine Hovakimyan ¹, Irina Petrushina ², Tatevik Antonyan ¹, Gor Chailyan ¹, Manush Ghazaryan ¹, Krzysztof L. Hyrc ³, Jean Paul Chadarevian ^{2,4} , Hayk Davtyan ^{2,4} , Mathew Blurton-Jones ^{2,4}, David H. Cribbs ², Michael G. Agadjanyan ^{1,‡} and Anahit Ghochikyan ^{1,*}

- ¹ Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA; kzagorski@immed.org (K.Z.); osvystun@uci.edu (O.K.); ahov@immed.org (A.H.); tantonyan@immed.org (T.A.); gorchailyan@gmail.com (G.C.); manush@immed.org (M.G.); magadjanyan@immed.org (M.G.A.)
- ² Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA; ipetrush@uci.edu (I.P.); jchadare@uci.edu (J.P.C.); hdavtyan@uci.edu (H.D.); mblurton@uci.edu (M.B.-J.); cribbs@uci.edu (D.H.C.)
- ³ The Hope Center of Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA; hyrc@wustl.edu
- ⁴ Department of Neurobiology & Behavior, University of California, Irvine, Irvine, CA 92697, USA
- * Correspondence: aghochikyan@immed.org; Tel.: +1-714-596-7821
- † These first authors equally contributed to this study.
- ‡ The last two authors equally contributed to this study.

Abstract: Post-translationally modified N-terminally truncated amyloid beta peptide with a cyclized form of glutamate at position 3 (pE₃Aβ) is a highly pathogenic molecule with increased neurotoxicity and propensity for aggregation. In the brains of Alzheimer's Disease (AD) cases, pE₃Aβ represents a major constituent of the amyloid plaque. The data show that pE₃Aβ formation is increased at early pre-symptomatic disease stages, while tau phosphorylation and aggregation mostly occur at later stages of the disease. This suggests that pE₃Aβ accumulation may be an early event in the disease pathogenesis and can be prophylactically targeted to prevent the onset of AD. The vaccine (AV-1986R/A) was generated by chemically conjugating the pE₃Aβ₃₋₁₁ fragment to our universal immunogenic vaccine platform MultiTEP, then formulated in Advax^{CPG} adjuvant. AV-1986R/A showed high immunogenicity and selectivity, with endpoint titers in the range of 10⁵–10⁶ against pE₃Aβ and 10³–10⁴ against the full-sized peptide in the 5XFAD AD mouse model. The vaccination showed efficient clearance of the pathology, including non-pyroglutamate-modified plaques, from the mice brains. AV-1986R/A is a novel promising candidate for the immunoprevention of AD. It is the first late preclinical candidate which selectively targets a pathology-specific form of amyloid with minimal immunoreactivity against the full-size peptide. Successful translation into clinic may offer a new avenue for the prevention of AD via vaccination of cognitively unimpaired individuals at risk of disease.

Keywords: Alzheimer's disease; vaccine; post-translational modification; pyroglutamate; prevention



Citation: Zagorski, K.; King, O.; Hovakimyan, A.; Petrushina, I.; Antonyan, T.; Chailyan, G.; Ghazaryan, M.; Hyrc, K.L.; Chadarevian, J.P.; Davtyan, H.; et al. Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer's Disease. *Int. J. Mol. Sci.* **2023**, *24*, 9797. <https://doi.org/10.3390/ijms24129797>

Academic Editor: Bruno Imbimbo

Received: 29 April 2023

Revised: 1 June 2023

Accepted: 1 June 2023

Published: 6 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Various immunotherapeutic approaches for treating and preventing Alzheimer's Disease (AD) have been developing for nearly a quarter century, yet an effective vaccine remains elusive [1–3]. One of the key issues with anti-Aβ immunotherapies is the inadequately late start of the treatment. Since the aggregation of Aβ and even neuronal loss occur years before the first cognitive symptoms, a successful therapeutic approach targeting Aβ needs to be initiated long before the onset of the symptoms and well before the accumulation of the pathological tau protein [4–6]. The treatment of cognitively unimpaired people at risk of disease would need to be extremely safe, minimally invasive, and

cost-effective to be viable. Yet, most immunotherapies currently in development are based on passive immunizations with high titers of exogenous humanized antibodies, which are costly, require regular infusions, and are often associated with serious side effects [7].

Vaccination, as opposed to passive immunotherapy, promotes the endogenous production of therapeutically potent antibodies for extended periods. Vaccines do not require monthly re-administration, which makes vaccination more affordable and less invasive [8]. These properties can address many of the limitations mentioned above and emphasize the need for a vaccine aimed at pathology-specific targets in cognitively unimpaired people at risk of AD.

One of the most promising targets is the N-terminally truncated pE₃Aβ. The pE₃Aβ species are present in great abundance in AD-associated plaques [9–11] and form soluble oligomers that potentially seed full-length Aβ_{1–42}. The pyroglutamate-modified peptides accumulate a decade prior to the symptom onset, yet their relative abundance in the AD brain is approximately threefold higher compared to the untruncated forms, making them a superior disease-specific target [12–19]. Furthermore, they are an active component of the amyloid cascade pathogenesis rather than a harmless bystander and capable of promoting the conversion of Aβ₄₂ into toxic oligomers in a prion-like manner [20–30]. The most valuable evidence in favor of targeting pE₃Aβ is the recent clinical trial performance of donanemab, a humanized IgG1 monoclonal antibody generated from mouse mAb, mE8-IgG2a [31,32]. Due to the rapid clearance of Aβ plaques and slowing of cognitive decline, donanemab has received Breakthrough Therapy designation from the FDA. However, despite being humanized, 90% of individuals treated with donanemab developed detectable anti-donanemab antibodies after a single injection, as opposed to 0.6% for currently approved aducanumab [33,34]. Subsequent administrations of donanemab can further increase the titers of these anti-donanemab antibodies, which may lead to diminishing efficacy of the drug and increased adverse events over time [35].

The general feasibility of vaccination against pE₃Aβ with high selectivity against untruncated forms of Aβ was first demonstrated in 2009 [36]. Since then, AFFITOPE AD03 (Affiris, Inc., San Francisco, CA, USA) has been the only anti-pE₃Aβ vaccine evaluated in a clinical trial. This study was terminated in 2013 after phase Ia completion in 2011, and no reports or peer-reviewed publications regarding the immunogenicity of this vaccine and the structure of mimotope peptide attached to KLH are available to this day [37]. A preclinical stage vaccine for pE₃Aβ (amyloid peptide fused with a tetanus T helper cell epitope, P2) with ~16-fold selectivity compared to the full-length peptide was reported by Li et al. [38]. Recently, AC Immune reported that antibodies generated in mice and non-human primates by an optimized version of the ACI-24 vaccine targeting Aβ_{1–15} bind also to pE₃Aβ due to the broad epitope coverage of the Aβ peptide [39]. However, this binding is not specific to a pyroglutamate-modified epitope of Aβ, and the titers of antibodies binding to pE₃Aβ are significantly lower than those binding to the full-length Aβ₄₂. Additionally, the “TAPAS” vaccine, which targets a stabilized cyclic form of Aβ_{1–14}, has been shown to generate antibodies recognizing pE₃Aβ. Antibodies generated by the TAPAS vaccine, as well as the TAP01 humanized antibody, showed therapeutic benefits in 5XFAD and Tg4–42 mouse models of AD [40].

In this study, taking advantage of the immunogenic and universal MultiTEP platform technology, we have developed and tested a vaccine candidate against pE₃Aβ in a stringent 5XFAD mouse model of AD [41–46].

The pyroglutamated aa 3–11 peptide was synthesized with C-terminal azide and chemically attached to the specially engineered version of MultiTEP carrier protein using copper-free click chemistry. The data below demonstrate that the generated conjugate vaccine is highly immunogenic and highly selective for pyroglutamate modification. More importantly, the vaccine shows promising therapeutic potential in the transgenic 5XFAD mouse model of AD, reducing both pE₃Aβ and full-length Aβ in their brain, despite only minimal immune response towards the full-size peptide generated by this novel vaccine.

2. Results

2.1. Preparation of the MultiTEP-Based Carrier Protein for Bioconjugation

The MultiTEP carrier protein was modified via a thiol-specific chemical reaction to enable the chemical attachment of post-translationally modified peptides, such as pyroglutamated A β_{3-11} . First, the pre-existing cysteines within the protein were mutated to serines to avoid the chemical modification of the epitopes containing them, while maximally preserving their structural properties. Then, the attachment sites were introduced by adding a linker containing three cysteines flanked on either side with four repeats of lysine-glutamate (KEKEKEKE). The highly hydrophilic linker was chosen to maximize the solvent exposure of the cysteines and reduce the steric hindrances during the chemical conjugations, allowing for up to three peptides to be attached to each molecule of MultiTEP. The carrier was then conjugated to the azide-labeled pEA β_{3-11} peptides using a Maleimide-PEG4-DBCO heterobifunctional crosslinker reagent.

The data presented in Figure 1 demonstrates the Coomassie-stained SDS PAGE, along with a western blot visualized with commercial anti-pE $_3$ A β polyclonal antibodies. The unconjugated carrier can be seen as a single band on the Coomassie stain, but not on the western blot since it does not contain the target epitopes. The conjugation product, on the other hand, is more heterogeneous with three defined bands most likely corresponding to the protein carrying 1–3 copies of the target epitope. Higher molecular weight species were also observed and likely oligomers of the conjugated proteins stained by the commercial anti-pE $_3$ A β polyclonal antibody.




Figure 1. Characterization of the conjugate. Analysis of the carrier and the conjugated product by SDS-PAGE, followed by Coomassie staining (A), and western blotting with anti-pE $_3$ A β commercial antibodies (B). Note the complete absence of signal in lane 1 of the western blot, indicating that all the bands detected in lane 2 contain the conjugated epitope pE $_3$ A β . M. Marker for molecular weight 1. Unconjugated MultiTEP carrier 2. Conjugation product with pE $_3$ A β .

2.2. Choosing the Mouse Model of AD

Evaluation of the 5XFAD mouse model of AD demonstrated a significant increase of the pE $_3$ A β in the cortex and hippocampus area at 6 months that further increases with age [22,47–50]. Accordingly, we bred these familial AD transgenic mice overexpressing human APP695 with Swedish, Florida, and London mutations, along with two mutations in the human PS1 in our vivarium and verified the presence of pE $_3$ A β depositions at eight months of age. Brain slices from the 5XFAD mouse model were imaged using confocal microscopy with fluorescently labeled antibodies specific to full-length A β_{42} or

N-terminally truncated pE₃Aβ. Signals from the two antibodies were collected in separate color channels and the images were merged as two pseudocolors to identify the relative localization and quantities of each form of Aβ. Figure 2A demonstrates that both forms of the amyloid protein were present in the brains of the animals, with the pyroglutamated form located primarily within the plaque core rather than in the diffuse regions seen in human pathology [51]. Since the 5XFAD animals bred in our animal facility had detectable deposits of pE₃Aβ, they have been deemed a valid model for testing vaccination-mediated clearance of this pathology.




Figure 2. Validation and immunization of transgenic animals. (A) Confocal microscopy confirms pyroglutamate-modified pE₃Aβ (blue) peptides within 6E10 positive (red; Aβ₁₋₁₇) Aβ aggregates in a 5XFAD transgenic mouse model of AD. 20× scale bar, 100 μm. Representative 40× scale bar, 50 μm. (B) Schematic depicting immunization study of 5XFAD mice injected (arrow) with AV-1986R/A vaccine, Advax^{CpG} adjuvant, or PBS (*n* = 12 M/12F mice per group). * AV-1986R/A is a pE₃Aβ-MultiTEP formulated in an Advax^{CpG} adjuvant.

2.3. Immunogenicity and Selectivity of the AV-1986R/A Vaccine in 5XFAD Mice

The 5XFAD mice were sorted into 3 groups, 12 males and 12 females in each, with 2 control groups (PBS or Advax^{CpG} adjuvant) and 1 experimental group for the vaccine candidate termed AV-1986R/A, consisting of the conjugation product formulated in the Advax^{CpG} adjuvant. The detailed schedule of immunizations and study can be seen in Figure 2B. The sera collected after the fourth immunization were evaluated by ELISA to quantify the antibody titers against the pE₃Aβ peptide, as well as against the unmodified Aβ₄₂. The endpoint titers against the pyroglutamate-modified peptide were significantly higher (*p* < 0.0001 Mann-Whitney U test), with the geometric mean titers being 74-fold higher against the pE₃Aβ. The effect was similar for male and female animals, with a slightly higher, but statistically insignificant, geometric mean ratio of the endpoint titers in females. The data is plotted in Figure 3.

To further evaluate the pE₃Aβ selectivity of the generated antibodies, we used an overlapping peptide library in competition ELISA. The data presented in Supplementary Figure S1 demonstrates that none of the alternative peptides efficiently bind to the pyroglutamate-specific antibodies, including the truncated Aβ₃₋₁₄ lacking the cyclic pE residue. However,

the minor $A\beta_{42}$ -specific antibodies were efficiently inhibited with peptides containing the residues 3–11, with the epitope likely spanning residues 3–11 or 4–11. The antibody titers after each immunization were plotted to demonstrate the immune response kinetics and can be found in Supplementary Figure S2. Finally, isotyping was performed for the major immunoglobulin types shown in Supplementary Figure S3.




Figure 3. Immunogenicity and selectivity. Endpoint titers of generated antibodies were evaluated in the sera of individual mice ($n = 24$) after the fourth immunization by ELISA. Bars indicate the geometric mean titer, and the x -axis indicates the target peptide in ELISA. Titers of generated antibodies specific to full-length $A\beta_{42}$ are significantly lower than titers of antibodies specific to pyroglutamate modified $A\beta_{3-11}$. The ratio of geometric mean titers of anti-pE₃A β to anti- $A\beta_{42}$ was 74:1. (A) Splitting of the data by sex showed similar results, with a 66:1 ratio for males ($n = 12$) and 83:1 for females ($n = 12$). (Y-scale is logarithmic) (B). 74:1. (A) Splitting of the data by sex showed similar results, with a 66:1 ratio for males ($n = 12$) and 83:1 for females ($n = 12$). (Y-scale is logarithmic) (B). **** is $p \leq 0.0001$, symbol “o” presents endpoint titers of Antibodies in the sera of an individual mouse.

2.4. Immunohistochemical Evaluation of Plaque-Clearing in 5XFAD Mice

Four weeks after the fifth immunization, mice were euthanized at the final age of 6.5 months old. The brains were harvested from all three groups for further assessment of vaccine efficacy, with one-half of each brain being sliced for immunohistochemical characterization. The microslices were first evaluated for pyroglutamated amyloid (anti-pE₃A β positive) to confirm primary target engagement and clearance. The positive area was compared between the three groups, and the data is plotted in Figure 4 along with representative images from AV-1986R/A-vaccinated- and control-animals. For both sexes, the tissue slices from the animals vaccinated with AV-1986R/A showed significantly less pE₃A β -specific staining when compared to either control ($p < 0.0001$ U test). This indicates that the generated antibodies can successfully remove the targeted pathological species within the brain with high efficacy.

Next, tissue slices were visualized with antibodies specific to non-pyroglutamated A β , specifically 6E10 mAb, which we previously used to detect the non-pyroglutamated plaques in the 5XFAD animals. Again, the tissue from the vaccinated animals showed a significant reduction of the positive area compared to either control, regardless of sex, as shown in Figure 5.




Figure 4. Clearance of pE3-positive plaque from the brains of 5xFAD mice quantified by immunohistochemistry. Brain sections from 5xFAD mice injected with the pE3-based vaccine formulated in Advax^{CpG} adjuvant were compared to brain sections from control animals injected with either Advax^{CpG} adjuvant or PBS. The sections were stained with commercial anti-pE3Aβ antibodies, and the pyroglutamated plaque-positive area was calculated and plotted. Brain slices from the vaccinated animals contained a significantly less anti-pE3Aβ positive area compared to either control with $p < 0.0001$ (****) (A). The splitting of data points to males (B) and females (C) resulted in the same intergroup relationship with $p < 0.0001$ (****) for each. No significant differences were observed between the 2 controls. Representative images are shown in panel (D), scale bars = 2.5 mm; enlarged hippocampal areas presented, scale bars = 500 μ m.

2.5. A β Content of 5XFAD Mouse Brain Extracts by ECLIA

Half of each brain was extracted to obtain soluble and insoluble fractions of A β for their quantitative analysis via the MesoScale Discovery electrochemiluminescent immunoassay (ECLIA) kit. The data obtained from the analysis of the soluble fractions are shown in Figure 6. The only statistically significant differences observed were between the male Advax^{CpG}-injected and AV-1986R/A-vaccinated animals, with a slight elevation of the soluble A β in the vaccine group, potentially suggesting solubilization of the plaque material by the antibodies. This effect may have been enhanced by the complex effects of the TLR9 agonists on brain homeostasis, which have been observed previously in the context of amyloid and AD [52–56].




Figure 5. Clearance of non-pyroglutamated A β plaque from the brains of 5XFAD mice quantified by immunohistochemistry. Brain sections from 5XFAD mice injected with the pE₃-based vaccine formulated in Advax^{CpG} adjuvant were compared to the brain sections from control animals injected with either Advax^{CpG} adjuvant or PBS. The sections were stained with commercial anti-A β monoclonal antibodies 6E10, and the positive area was calculated and plotted. Brain slices from the vaccinated animals contained significantly less 6E10 positive area compared to either control, with $p = 0.013$ (*) for the Advax^{CpG} control and $p = 0.003$ (**) for the PBS control (**A**). Splitting the data by sex resulted in $p = 0.033$ (*) for Advax^{CpG} in males; $p = 0.002$ (**) for PBS in males (**B**); $p = 0.016$ (*) for Advax^{CpG} in females; $p = 0.011$ (*) for PBS in females (**C**). No significant differences were observed between the two controls. Representative images are shown in panel (**D**), scale bars = 2.5 mm; enlarged hippocampal areas presented scale bars = 500 μ m.

The remaining insoluble fractions of the brain extracts were further solubilized with formic acid and assayed using the same method. The data obtained from the analysis of the insoluble fractions are plotted in Figure 7. Vaccinated animals showed a significant reduction of insoluble amyloid when compared to either control. Interestingly, the reduction was only significant in females. Despite the absence of statistical significance by the U

test, the amyloid load in half of the vaccinated males (but none from controls) was below the minimum limit of quantitation of the assay, suggesting that the absence of statistical significance was due to the insufficient statistical power of the experimental design. This is, in general, a limitation that can be seen with various mouse models of AD that are only partially replicating the very complex human Alzheimer's disease.




Figure 6. Clearance of soluble A β from the brains of 5XFAD mice quantified by ECLIA. Brain tissue samples from 5XFAD mice injected with the pE₃A β -based vaccine formulated in an Advax^{CpG} adjuvant were compared to brain sections from control animals injected with either Advax^{CpG} adjuvant or PBS. The tissue samples were extracted with a T-PER reagent, and the extract was separated by centrifugation into a soluble fraction (supernatant) and an insoluble fraction (pellet). The soluble fraction was normalized by protein content using bicinchoninic acid assay and loaded onto an ECLIA plate. The concentration of human A β ₄₂ was measured and plotted. The vaccine group had a significantly higher level of (** $p = 0.0076$) human A β ₄₂ when compared to the Advax^{CpG} group, but not when compared to the PBS group (A). When the animals were split by sex, the effect persisted in males (B) with ** $p = 0.0083$, but no significant differences were seen between the groups in females (C). Groups injected with the PBS, Advax^{CpG}, and pE₃A β -based vaccines are shown in different colors.




Figure 7. Clearance of insoluble A β from the brains of 5XFAD mice quantified by ECLIA. The insoluble pellets obtained from the T-PER extraction were solubilized in formic acid and normalized by the protein concentration in the soluble fraction. The solubilized pellets were then neutralized and loaded onto an ECLIA plate, and the concentration of human A β ₄₂ was measured and plotted. The vaccine group had a significantly lower level of human A β ₄₂ compared to either control, with ** $p = 0.0047$ for PBS and ** $p = 0.0033$ Advax^{CpG} group (A). When the animals were split by sex, no significant differences were seen between the groups in males (B), while the effect persisted in females, with * $p = 0.0145$ for PBS and ** $p = 0.0041$ for the Advax^{CpG} group (C). Groups injected with PBS, Advax^{CpG}, and pE₃A β -based vaccines are shown in different colors.

3. Discussion

Alzheimer's disease is one of the most challenging public health emergencies of our time. Currently, an estimated 35 million people live with AD globally [57]. Since age is the primary risk factor for developing AD, the increasing healthcare quality and life expectancy inevitably leads to an increased AD morbidity. Affected individuals undergo gradual cognitive deterioration and eventually require assistance for basic tasks, such as eating and bathing. In the final stages, the degenerative changes in the brain can perturb their ability to swallow, cough, and breathe. Along with the obvious human pain and suffering, AD also has an immense economic footprint for developed countries: just in the United States, where about 6.7 million people live with AD, the costs are estimated to be around \$600 billion, which is why the research of treatments for AD is of strategic importance [58]. Since A β aggregation is currently considered the primary driving factor of AD pathogenesis, a significant portion of research efforts are aimed at restoring and protecting the normal homeostasis of A β in the brain. However, to-date, no reliable means of prevention or treatment exists for this debilitating disorder.

Recently, some success has been made in the realm of AD immunotherapy. More specifically, two monoclonal antibodies targeting A β oligomers (fully human, aducanumab) and protofibrils (humanized, lecanemab) were approved by the FDA. A third antibody targeting pyroglutamate-modified pE₃A β (donanemab) is expected to also be approved. Despite these positive results, the overall epidemiological situation is still dire. It is important to understand that while the efficacy of the monoclonals is quantifiable, it is hardly meaningful in terms of an added quality of life.

Our group has long been a proponent of a more proactive approach to AD immunotherapy, using active vaccines to prevent the onset rather than ameliorate or treat the symptoms. We have demonstrated, in animal models, that by the time the disease is symptomatic, the neuronal damage and tau-pathology are self-sustaining, and removal of the amyloid has little to no effect. In this paradigm, the applicability of monoclonal antibodies becomes questionable since they require frequent and costly injections that would not be appealing or affordable to the general population as a preventative measure.

Vaccines are far more viable as a preventative therapeutic and have been used for exactly that purpose for centuries. Yet, no immunogenic, safe, and effective vaccine has yet been approved for AD. Multiple therapeutic vaccines against AD have failed in clinical trials due to poor immunogenicity, inefficacy, and serious adverse events [59]. These failures are part of a bigger trend in the field of anti-A β therapeutics, with antibodies and small molecules aimed at reducing production and increasing the elimination of A β peptides in people with prodromal (Mild Cognitive Impairment) or mild-moderate AD. Most of these therapeutics either did not ameliorate AD or worsened it [59–64]. We believe that one of the fundamental reasons for the failure of many anti-amyloid therapeutics stems from the obsolete notion that A β peptides are cellular waste with no physiological value or function, leading to approaches designed to indiscriminately target all isoforms and species of A β [65]. Current evidence suggests that A β peptides have diverse functions in normal brain homeostasis, and the complete depletion of these peptides from the brain affects neuroplasticity, memory, axonal regeneration, and other normal neuronal processes [66,67].

In this work, we chose to target a more pathology-specific isoform of A β to generate a safer vaccine for prophylactic use in healthy individuals. Specifically, we chose the post-translationally modified pE₃A β based on the high pathogenicity and prevalence of this species in AD [9,11,13,15,17,18]. We hypothesize that targeting this species may lead to superior safety and efficacy, unlike previous A β vaccine efforts, by reducing the disease-specific A β .

To achieve robust and reliable immunogenicity, we applied our well-characterized universal vaccine platform MultiTEP, which is currently being evaluated in multiple preclinical IND enabling studies [42–44,46,68] and is in a first-in-human DNA vaccine Phase I clinical trial (NCT05642429). This vaccine platform is designed to induce strong immune responses in genetically diverse populations and potentially in immunosenescence individuals by

activating pre-existing memory T helper cells with select universal foreign T helper (Th) epitopes. Such an approach is highly advantageous since the target population of pre-AD vaccines is generally 50+ years old who may have a senescent naïve Th cell pool, yet robust memory Th cells acquired in youth [69]. Additionally, using short, well-characterized universal epitopes allows for the minimalistic design of the MultiTEP platform, reducing potential safety concerns. Finally, the MultiTEP protein spontaneously assembles into oligomeric nanoparticles, thus protecting the target epitopes from rapid degradation, efficiently delivering them to antigen-presenting cells, and providing additional stimulation to the B cells due to the simultaneous presentation of multiple copies of the antigen [44]. Thus, our preclinical data demonstrated exceptionally potent and robust immune responses towards various neurodegeneration-associated target molecules [42,43,46], and, in this work, we presented the first MultiTEP-based conjugate vaccine for a post-translationally modified target—specifically, pE₃Aβ.

The studies outlined in this manuscript demonstrate that our vaccine candidate induced robust and selective immune responses against the target isoform and led to a marked reduction of AD-like pathology in the 5XFAD mouse model of aggressive AD. We observed a more significant reduction of insoluble Aβ in female mice than in males. On the contrary, in our previous study, we observed a more substantial reduction of insoluble Aβ in the brains of male bigenic 5XFADxPS19 mice than in females when immunized with the Aβ vaccine formulated with the same adjuvant [46]. These gender-specific differences in vaccine efficacy in mouse models may arise from various factors, including environmental, genetic, and hormonal factors, and the severity of amyloid pathology.

It is important to note that the vaccine reduced not only pyroglutamated-Aβ plaques, but also non-pyroglutamated aggregates. This is especially promising since pE₃Aβ is not an early component in 5XFAD mice as opposed to real AD pathogenesis in humans. This implies that the early clearance of pE₃Aβ could be even more effective in ameliorating the downstream pathological events of the disease and shows particularly encouraging potential considering the current lack of preventive vaccinations for people at risk of AD. The next steps in developing this vaccine require further optimizing the chemistry for the conjugation of the pE₃Aβ_{3–11} peptide to MultiTEP to improve yield and stability, as well as manufacturing of cGMP vaccine for preclinical safety-toxicology studies. Once completed, this data will allow us to apply for an IND and initiate a Phase 1 clinical trial for the assessment of the safety and immunogenicity of this novel drug product in humans.

4. Materials and Methods

4.1. Preparation of the MultiTEP-Based Vaccine for pE₃Aβ by Click Chemistry

Prior reports on the structures of oligomeric and fibrillar species of amyloid showed that the region between residues 1 and 14 are highly surface-exposed and the tyrosine 10 is solvent exposed in Aβ₄₂ oligomers to a similar extent to that found in the unfolded monomer [70,71]. These data and the epitope prediction tool described in [72] were used to determine and select the target peptide length [70–72].

A version of the MultiTEP protein with C-to-S substitutions within the T helper epitopes, as well as an N-terminal zwitterionic linker bearing three cysteines, was expressed and purified via chromatography on Nickel (II) nitrilotriacetate resin (Ni-NTA, Qiagen, Redwood City, CA), followed by a second purification on HisPur Cobalt super-flow resin (ThermoFisher Scientific, Chino, CA). All purification steps were performed in the presence of 8M urea, and elution was performed by a gradual reduction of the pH. Fractions eluted at different pH points were collected, and SDS-PAGE, followed by Coomassie staining, was used to identify the fractions with the highest purity of the protein. SDS-PAGE was performed as described above, and Coomassie staining was performed as described previously [73]. The overall structure of the purified protein is shown in Supplementary Figure S4.

Selected fractions were combined and transferred to 6 M guanidinium hydrochloride in PBS at pH 6.6. This slightly acidic condition ensures maximal selectivity of the maleimide

coupling to thiols since the amines are only reactive in the deprotonated state. The cysteines were reduced by the addition of TCEP (tris(2-carboxyethyl)phosphine) at a molar ratio of 1:9 MultiTEP to TCEP, corresponding to a 3-fold molar excess of TCEP to cysteine residues [74]. The mixture was incubated for 2 h at 37 °C based on the reported reduction kinetics. Next, the DBCO-PEG4-Maleimide (Click Chemistry Tools, Scottsdale, AZ) linker was added at a 1:15 molar ratio of thiol to maleimide and allowed to incubate for 16 h at room temperature [72]. The product was purified by dialysis to remove the excess TCEP and DBCO-PEG4-Maleimide to prevent their reaction with the azide-labeled peptide. The azide-labeled synthetic peptide with the sequence pEFRHDSGYE-GGGGS-Azidolysine (Genscript, Piscataway, NJ) was added in a 1:6 molar ratio of MultiTEP to peptide and incubated for 24 h at 4 °C. The final purification was done by dialysis in 6 M guanidinium to remove the excess peptide, followed by refolding via gradual reduction of the guanidinium concentration in the dialysis buffer. Finally, the pH was adjusted to physiological in PBS, and doses were aliquoted and frozen. The summary of reactions is presented in Supplementary Figure S5.

4.2. Mouse Model Selection

The 5XFAD mice (B6SJL-Tg(APP^{Sw}FILon, PSEN1^{M146L}*L286V)6799Vas/-Mmjax) from Jackson Lab (Bar Harbor, ME, USA) were used in this study. These animals are maintained on a congenic C57Bl6/J background and co-expresses the human amyloid precursor protein (APP695) carrying the Swedish, Florida, and London mutations, as well as a human presenilin-1 (PS1) transgene carrying the M146L and L286V mutations under the Thy-1 promoter. Both APP and PS1 transgenes are co-integrated and thus, co-inherited. This transgenic mouse model was selected based on an aggressive pathology phenotype and rapid disease progression. These mice develop amyloid plaque as early as 2 months of age, which allowed for a faster experimental timeline. Most importantly, these animals develop deposits of pyroglutamated amyloid at 6 months of age [22,47–49].

Both female and male animals were used in this study. All animals were housed in a temperature and light-cycle-controlled facility. Their care was under the guidelines of the National Institutes of Health and an approved IACUC protocol at the University of California, Irvine.

4.3. Experimental Protocols

5XFAD mice were immunized with AV-1986R/A (20 µg/mouse/injection), formulated with an Advax^{CpG} adjuvant (Vaxine Pty Ltd., Adelaide, Australia) at 1 mg/mouse/injection.

Control groups of 5XFAD mice were injected with an Advax^{CpG} adjuvant only or PBS. All mice were injected five times intramuscularly (Figure 2 B). Sera were collected 14 days after the fourth immunization, and anti-A β ₄₂ and anti-pE₃A β antibody responses were analyzed. At the age of 6.5 months old, mice were terminated, and brains were collected for biochemical and immunohistological analysis.

4.4. ELISA

There were 96-well high binding plates separately coated with 1 µg/well (in 100 µL; Carbonate-Bicarbonate buffer, pH 9.6, o/n at 4 °C) of a pE₃A β peptide (Genscript, Piscataway, NJ, USA) and unmodified A β ₄₂ (Genscript, Piscataway, NJ, USA). The next day, coated plates were washed 3 times and blocked with a blocking buffer (3% dry, non-fat milk in TBST, 200 µL/well, o/n at 4 °C). Sera samples were diluted 5-fold, serially starting at 1:1000 and 1:200 for the detection of anti-pE₃A β and anti-A β ₄₂, respectively (in 0.3% dry, non-fat milk in TBST, 100 µL/well), then added to the plates and incubated o/n at 4 °C. The plates were washed 3 times with TBST, then the secondary antibody, HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories 1:2500 dilution) (cat#115-036-003), was added and incubated for 1 h at room temperature.

HRP-conjugated anti-IgG1, IgG2ab, IgG2b, and IgM-specific antibodies (Bethyl Laboratories, Inc., Montgomery, TX) were used to characterize the isotype profiles of anti-pE₃A β antibodies in the pooled sera at a dilution of 1:1000 (Figure S3).

Plates were washed 3 times with TBST before adding a 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution (Cat# 34029, ThermoFisher Scientific, Chino, CA, USA). The reaction was stopped after 5 min by adding 2N sulfuric acid. The OD at 450 nm was measured with a FilterMax F5 microplate reader. Endpoint titers of antibodies in mice sera were calculated as the reciprocals of the highest sera dilutions that gave an optical density reading thrice above the cutoff. The cutoff was determined as the titer of pre-immune sera at the same dilution.

4.5. Brain Extraction

Single hemispheres, previously frozen on dry ice and stored at -80°C , were crushed on dry ice using a mortar and pestle. First, soluble brain fraction was extracted. Approximately 1/3 of each powdered hemisphere was homogenized in 250 μL of the protein extraction buffer (mixture of T-PER (ThermoFisher Scientific, Chino, CA, cat# 78510), 1 \times phosphatase inhibitors, and 1 \times EDTA (ThermoFisher Scientific, Chino, CA, REF 78426), 1 \times protease inhibitors (ThermoFisher Scientific, Chino, CA, REF 78429)). Then homogenates were centrifuged at $16,000\times g$ for 15 min at 4°C and supernatants were collected. Then, 150 μL of the protein extraction buffer was added to the pellets, and they were homogenized, centrifuged, and supernatants collected again to extract the rest of the soluble fraction. Final pellets were stored at -80°C for further extraction of the insoluble fraction. Two soluble fractions were mixed, and the total protein concentration in the mixture was detected using a BCA assay. Then, 100 μL of 1 mg/mL of each soluble fraction was prepared using the T-PER buffer as a diluent. Stocks and 100 μL of 1mg/mL samples were frozen at -80°C for further use. Samples were used for quantitative biochemical analysis (by ECLIA) of human A β at 25 μg per well.

Second, insoluble brain fraction was extracted from the pellets stored at -80°C . Then, 250 μL of 70% Formic Acid (FA) was added to each pellet. Pellets were centrifuged at 16,000 g for 30 min at 4°C , and supernatants (insoluble fractions) were collected. Insoluble fractions were normalized based on the protein concentrations of soluble fractions obtained on the BCA assay. Then, 50 μL aliquots of normalized samples were frozen at -80°C for consequent use.

Prior to analyses, a neutralization buffer (1 M Tris base, 0.5 M NaH₂PO₄, 0.05% NaN₃) was added to the normalized insoluble fractions. The pH of the samples was adjusted to 7 using 5N NaOH. Then, 10,000-fold dilutions of the neutralized samples were used for biochemical analyses.

Quantitative biochemical analysis of human A β was conducted using a commercially available electrochemiluminescent multiplex assay system: Meso Scale Discovery (MSD, Rockville, MD). A V-PLEX human A β peptide panel (6E10 capture antibody) kit was used for simultaneous measurement of A β ₃₈, A β ₄₀, and A β ₄₂ in both soluble and insoluble protein fractions.

4.6. Immunohistochemistry

Prior to the brain collection, mice were anesthetized with an intraperitoneal injection of a 150 mg/kg Nembutal Sodium Solution (Akorn, Inc., Lake Forest, IL, USA), then perfused with 36 mL of 1 \times PBS (pH 7.4) using a peristaltic pump (12 mL/min). Brains were extracted and half-brains postfixed in 4% PFA for 48 h, washed in PBS, immersed in 30% sucrose for 48 h, and sectioned coronally at 40 μm thickness using the microtome (Leica SN2010R). Sections were collected into 12-well plates to obtain the series of equally-spaced sections throughout each brain, stored in PBS + 0.05% sodium azide.

Prior to IHC, 12 equally spaced tissue sections from each half-brain were washed in Tris buffer, mounted onto slides, air-dried at RT, incubated at 60°C for 20 min for better attachment, and cooled down to RT. Epitope retrieval was performed using a 0.1 M citrate

buffer (Fisher Scientific, Waltham, MA, USA, Erpedia, cat # AP-9003-500) diluted according to the manufacturer's instructions, and pre-warmed to 90 °C. The batches of slides carefully placed in incubation racks were immersed in the citrate buffer bath for 20 min at 90 °C. After cooling down to RT, slides were placed in a multi-sample staining tray and washed in 3 changes of Tris buffer for 5 min each, then once in Tris A (Thermo Scientific, Waltham, MA, USA, cat # 28360) diluted according to manufacturer's instruction for 5 min, and once in Tris B (1% BSA in Tris A) for 10 min.

For the detection of pE₃-positive plaques, each incubation chamber (GRACE Bio-Labs, Bend, OR, USA, cat.# 645402) was filled up with 230 µL of an Abeta-pE₃ antibody (Synaptic Systems SYSY, Göttingen, Germany, Cat# 218003) diluted in Tris B at 1:200, covered with inverted slide, and all slides were placed in a tightly covered container and incubated overnight at 4 °C.

On the next day, the chambers were opened, and the slides were washed twice in Tris A for 5 min and in Tris B for 10 min. Slides were then placed in incubation chambers filled with the secondary Biotin-SP donkey anti-rabbit IgG specific antibody (Jackson Immuno Research Laboratories, West Grove, PA, USA, #711-065-152) diluted in Tris B/4% donkey normal serum at 1:400. After 1 h at RT, the slides were washed again in Tris A twice for 5 min; then endogenous peroxidase was blocked by incubation in freshly prepared peroxidase blocking solution (10% methanol, 3% H₂O₂ in Tris buffer) for 10 min at RT, and finally washed three times in Tris A for 5 min and once in Tris B for 10 min at RT.

Vectastain® Elite® ABC kit (Vector Laboratories, Burlingame, CA, USA, cat # PK-6100) was used for enzyme conjugation. ABC reagent mix diluted in Tris B according to the manufacturer's instructions was prepared 30 min prior to incubation. Slides were chambered and incubated in ABC for 1 h at RT. Chambers were disassembled, and the slides were washed twice for 5 min in Tris, then in dH₂O for 5 min. Slides were placed face-up on the flat surface to air-dry for a few min. Finally, sections were stained using the DAB (3,3'-diaminobenzidine) substrate kit (Vector Laboratories, Burlingame, CA, USA, # SK-4100). The DAB solution mix was made according to the manufacturer's instructions, and a few drops were added to each slide to cover the surface. After the color development with similar incubation intervals maintained for each slide, the slides were washed twice in Tris A and once in dH₂O for 5 min. Slides were dehydrated in 50%, 70%, 95%, and 100% ethanol for 3 min in each, then cleared with 2 changes of Xylenes (Ibis Scientific, Las Vegas, NV, USA, #LC269704) for 10 min each, and coverslipped using the DEPEX (Fisher Scientific, Waltham, MA, USA, #50-980-372) mounting media, both according to manufacturer's instructions.

For detection of the non-pyroglutamated Aβ plaques, a similar protocol was used with a commercial anti-Aβ monoclonal antibody 6E10 (Biolegend, San Diego, CA, USA, #SIG-39320) at a 1:800 dilution with the secondary Biotin-SP donkey anti-mouse IgG specific antibody (Jackson Immuno Research Laboratories, West Grove, PA, USA, #715-065-151) diluted in TrisB/4% donkey normal serum at 1:400.

4.7. Whole-Slide Imaging and Data Analysis

Nine 40 µm sections per brain equally spaced between points +1.18 and −4.24 mm, relative to Bregma, were analyzed for all staining experiments.

The whole slide imaging for the assays was provided by the Alafi Neuroimaging laboratory at Washington University School of Medicine (St. Louis, MO, USA). The slides were digitized using a whole slide scanner (Nanozoomer 2.0 HT, Hamamatsu, Bridgewater, NJ, USA). The whole slide images were collected through an Olympus UPlanSApo 20×/0.75 lens and captured using the NDP.view2 digital slide viewer software (Hamamatsu Corporation, Bridgewater, NJ, USA). Quantification was performed using a digital pathology software (Visiormorph, Broomfield, CO, USA).

4.8. Confocal Microscopy

Then, 40- μ m brain sections from 8 month old 5XFAD mice were stained with rabbit anti-A β pE3 [Pyro Glu3] antibody (SYSY, 1:200) and 6E10 antibody (BioLegend, 1:1000), as described in [46]. Immunofluorescent sections were visualized and captured using an Olympus FX 1200 confocal microscope. Representative images represent confocal Z-stacks (12 slices at 1.79-micron step intervals) taken at 40 \times magnification, and Z-stacks (12 slices at 1.51-micron step intervals) taken at 20 \times magnification [46].

4.9. Data Analysis and Graphing

Statistical analysis was performed by the Mann–Whitney U test using the GraphPad Prism software (version 9, GraphPad Prism, San Diego, CA, USA).

5. Conclusions

The current immunotherapeutic strategies for AD are primarily aimed at the treatment of early symptomatic patients with monoclonal antibodies. A more proactive approach based on immunoprevention of AD in healthy individuals at risk of disease is contingent upon the emergence of novel biomarkers for the prediction of AD prior to pathology onset. Multiple minimally invasive biomarkers are currently being developed, refs. [75–81] and their application in clinical setting will outline a broad population of otherwise healthy individuals who may benefit from prophylactic vaccination against AD.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms24129797/s1>.

Author Contributions: Conceptualization, K.Z., A.G. and M.G.A.; methodology, K.Z. and O.K.; investigation, K.Z., O.K., A.H., I.P., J.P.C. and H.D.; Formal analyses, T.A., M.G., G.C. and K.L.H.; supervision, A.G. and M.G.A.; writing original draft preparation, K.Z.; writing—review and editing, A.G., M.G.A., D.H.C., M.B.-J. and J.P.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by funding from the NIH (R01-AG020241). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Institutional Review Board Statement: All animal procedures were performed in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals, and in compliance with an approved IACUC (Institutional Animal Care and Use Committee) protocol at the University of California, Irvine (UCI).

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated or analyzed during this study are included in this article and materials are available from the corresponding author on reasonable request.

Acknowledgments: We thank Gary D. London from Alafi Neuroimaging Laboratory at Hope Center for Neurological Disorders for the slide processing.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

pE3A β	N-terminally truncated amyloid beta peptides with a cyclized glutamate at position 3
AD	Alzheimer's Disease
ECLIA	Electrochemiluminescent Immunoassay
IHC	Immunohistochemistry
KLH	Keyhole Limpet Hemocyanin
ELISA	Enzyme-Linked Immunoassay

References

1. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* **1999**, *400*, 173–177. [[CrossRef](#)] [[PubMed](#)]
2. Kwan, P.; Konno, H.; Chan, K.Y.; Baum, L. Rationale for the development of an Alzheimer's disease vaccine. *Hum. Vaccines Immunother.* **2020**, *16*, 645–653. [[CrossRef](#)]
3. Agadjanyan, M.G.; Petrovsky, N.; Ghochikyan, A. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. *Alzheimer's Dement.* **2015**, *11*, 1246–1259. [[CrossRef](#)] [[PubMed](#)]
4. Vermunt, L.; Sikkes, S.A.M.; van den Hout, A.; Handels, R.; Bos, I.; van der Flier, W.M.; Kern, S.; Ousset, P.J.; Maruff, P.; Skoog, I.; et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimer's Dement.* **2019**, *15*, 888–898. [[CrossRef](#)] [[PubMed](#)]
5. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. *Nat. Rev. Drug Discov.* **2011**, *10*, 698–712. [[CrossRef](#)]
6. Viola, K.L.; Klein, W.L. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. *Acta Neuropathol.* **2015**, *129*, 183–206. [[CrossRef](#)]
7. Mafi, J.N.; Leng, M.; Arbanas, J.C.; Tseng, C.H.; Damberg, C.L.; Sarkisian, C.; Landon, B.E. Estimated Annual Spending on Aducanumab in the US Medicare Program. *JAMA Health Forum* **2022**, *3*, e214495. [[CrossRef](#)]
8. Marciani, D.J. Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine. *Research* **2019**, *2019*, 5341375. [[CrossRef](#)]
9. Sullivan, C.P.; Berg, E.A.; Elliott-Bryant, R.; Fishman, J.B.; McKee, A.C.; Morin, P.J.; Shia, M.A.; Fine, R.E. Pyroglutamate-Abeta 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Abeta 11 forming the central core. *Neurosci. Lett.* **2011**, *505*, 109–112. [[CrossRef](#)]
10. Liu, K.; Solano, I.; Mann, D.; Lemere, C.; Mercken, M.; Trojanowski, J.Q.; Lee, V.M. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: Implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. *Acta Neuropathol.* **2006**, *112*, 163–174. [[CrossRef](#)]
11. Wirths, O.; Erck, C.; Martens, H.; Harmeier, A.; Geumann, C.; Jawhar, S.; Kumar, S.; Multhaup, G.; Walter, J.; Ingelsson, M.; et al. Identification of low molecular weight pyroglutamate A β oligomers in Alzheimer disease: A novel tool for therapy and diagnosis. *J. Biol. Chem.* **2010**, *285*, 41517–41524. [[CrossRef](#)] [[PubMed](#)]
12. Thal, D.R.; Walter, J.; Saïdo, T.C.; Fandrich, M. Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease. *Acta Neuropathol.* **2015**, *129*, 167–182. [[CrossRef](#)] [[PubMed](#)]
13. Mandler, M.; Rockenstein, E.; Ubhi, K.; Hansen, L.; Adame, A.; Michael, S.; Galasko, D.; Santic, R.; Mattner, F.; Masliah, E. Detection of peri-synaptic amyloid-beta pyroglutamate aggregates in early stages of Alzheimer's disease and in AbetaPP transgenic mice using a novel monoclonal antibody. *J. Alzheimer's Dis.* **2012**, *28*, 783–794. [[CrossRef](#)] [[PubMed](#)]
14. Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; et al. Glutaminy cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. *Nat. Med.* **2008**, *14*, 1106–1111. [[CrossRef](#)] [[PubMed](#)]
15. Harigaya, Y.; Saïdo, T.C.; Eckman, C.B.; Prada, C.M.; Shoji, M.; Younkin, S.G. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochem. Biophys. Res. Commun.* **2000**, *276*, 422–427. [[CrossRef](#)]
16. Gunn, A.P.; Wong, B.X.; Johanssen, T.; Griffith, J.C.; Masters, C.L.; Bush, A.I.; Barnham, K.J.; Duce, J.A.; Cherny, R.A. Amyloid-beta Peptide Abeta3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. *J. Biol. Chem.* **2016**, *291*, 6134–6145. [[CrossRef](#)]
17. Portelius, E.; Lashley, T.; Westerlund, A.; Persson, R.; Fox, N.C.; Blennow, K.; Revesz, T.; Zetterberg, H. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. *Neurodegener. Dis.* **2015**, *15*, 50–57. [[CrossRef](#)]
18. Portelius, E.; Bogdanovic, N.; Gustavsson, M.K.; Volkman, I.; Brinkmalm, G.; Zetterberg, H.; Winblad, B.; Blennow, K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol.* **2010**, *120*, 185–193. [[CrossRef](#)]
19. Piccini, A.; Russo, C.; Gliozzi, A.; Relini, A.; Vitali, A.; Borghi, R.; Giliberto, L.; Armirotti, A.; D'Arrigo, C.; Bachi, A.; et al. beta-amyloid is different in normal aging and in Alzheimer disease. *J. Biol. Chem.* **2005**, *280*, 34186–34192. [[CrossRef](#)]
20. Russo, C.; Violani, E.; Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G.; Benatti, U.; D'Arrigo, C.; Patrone, E.; Carlo, P.; et al. Pyroglutamate-modified amyloid beta-peptides–AbetaN3(pE)–strongly affect cultured neuron and astrocyte survival. *J. Neurochem.* **2002**, *82*, 1480–1489. [[CrossRef](#)]
21. He, W.; Barrow, C.J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. *Biochemistry* **1999**, *38*, 10871–10877. [[CrossRef](#)] [[PubMed](#)]
22. Wirths, O.; Breyhan, H.; Cynis, H.; Schilling, S.; Demuth, H.U.; Bayer, T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. *Acta Neuropathol.* **2009**, *118*, 487–496. [[CrossRef](#)] [[PubMed](#)]

23. Grochowska, K.M.; Yuanxiang, P.; Bar, J.; Raman, R.; Brugal, G.; Sahu, G.; Schweizer, M.; Bikbaev, A.; Schilling, S.; Demuth, H.U.; et al. Posttranslational modification impact on the mechanism by which amyloid-beta induces synaptic dysfunction. *EMBO Rep.* **2017**, *18*, 962–981. [[CrossRef](#)]
24. Camargo, L.C.; Schoneck, M.; Sangarapillai, N.; Honold, D.; Shah, N.J.; Langen, K.J.; Willbold, D.; Kutzsche, J.; Schemmert, S.; Willuweit, A. PEAbeta Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. *Int. J. Mol. Sci.* **2021**, *22*, 7062. [[CrossRef](#)] [[PubMed](#)]
25. De Kimpe, L.; van Haastert, E.S.; Kaminari, A.; Zwart, R.; Rutjes, H.; Hoozemans, J.J.; Scheper, W. Intracellular accumulation of aggregated pyroglutamate amyloid beta: Convergence of aging and Abeta pathology at the lysosome. *Age* **2013**, *35*, 673–687. [[CrossRef](#)]
26. Kumar-Singh, S.; De Jonghe, C.; Cruts, M.; Kleinert, R.; Wang, R.; Mercken, M.; De Strooper, B.; Vanderstichele, H.; Lofgren, A.; Vanderhoeven, I.; et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. *Hum. Mol. Genet.* **2000**, *9*, 2589–2598. [[CrossRef](#)]
27. Lalowski, M.; Golabek, A.; Lemere, C.A.; Selkoe, D.J.; Wisniewski, H.M.; Beavis, R.C.; Frangione, B.; Wisniewski, T. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. *J. Biol. Chem.* **1996**, *271*, 33623–33631. [[CrossRef](#)]
28. Saido, T.C.; Iwatsubo, T.; Mann, D.M.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. *Neuron* **1995**, *14*, 457–466. [[CrossRef](#)]
29. Nussbaum, J.M.; Schilling, S.; Cynis, H.; Silva, A.; Swanson, E.; Wangsanut, T.; Tayler, K.; Wiltgen, B.; Hatami, A.; Ronicke, R.; et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. *Nature* **2012**, *485*, 651–655. [[CrossRef](#)]
30. Bayer, T.A. Pyroglutamate Abeta cascade as drug target in Alzheimer's disease. *Mol. Psychiatry* **2022**, *27*, 1880–1885. [[CrossRef](#)]
31. Mintun, M.A.; Lo, A.C.; Duggan Evans, C.; Wessels, A.M.; Ardayfio, P.A.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys, M.; et al. Donanemab in Early Alzheimer's Disease. *N. Eng. J. Med.* **2021**, *384*, 1691–1704. [[CrossRef](#)] [[PubMed](#)]
32. Demattos, R.B.; Lu, J.; Tang, Y.; Racke, M.M.; Delong, C.A.; Tzaferis, J.A.; Hole, J.T.; Forster, B.M.; McDonnell, P.C.; Liu, F.; et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. *Neuron* **2012**, *76*, 908–920. [[CrossRef](#)] [[PubMed](#)]
33. Aduhelm. ADUHELM™ (Aducanumab-Avwa) Injection, for Intravenous Use. Initial U.S. Approval: 2021. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf (accessed on 15 March 2023).
34. Lowe, S.L.; Willis, B.A.; Hawdon, A.; Natanegara, F.; Chua, L.; Foster, J.; Shcherbinin, S.; Ardayfio, P.; Sims, J.R. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. *Alzheimer's Dement.* **2021**, *7*, e12112. [[CrossRef](#)] [[PubMed](#)]
35. Vaisman-Mentesh, A.; Gutierrez-Gonzalez, M.; DeKosky, B.J.; Wine, Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation following Treatment with Monoclonal Antibodies. *Front. Immunol.* **2020**, *11*, 1951. [[CrossRef](#)]
36. Acero, G.; Manoutcharian, K.; Vasilevko, V.; Munguia, M.E.; Govezensky, T.; Coronas, G.; Luz-Madrigal, A.; Cribbs, D.H.; Gevorkian, G. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. *J. Neuroimmunol.* **2009**, *213*, 39–46. [[CrossRef](#)]
37. Cynis, H.; Frost, J.L.; Crehan, H.; Lemere, C.A. Immunotherapy targeting pyroglutamate-3 Abeta: Prospects and challenges. *Mol. Neurodegener.* **2016**, *11*, 48. [[CrossRef](#)]
38. Li, G.; Hu, Z.W.; Chen, P.G.; Sun, Z.Y.; Chen, Y.X.; Zhao, Y.F.; Li, Y.M. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid beta Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice. *ACS Chem. Neurosci.* **2017**, *8*, 454–459. [[CrossRef](#)]
39. Vukicevic, M.; Fiorini, E.; Siegert, S.; Carpintero, R.; Rincon-Restrepo, M.; Lopez-Deber, P.; Piot, N.; Ayer, M.; Rentero, I.; Babolin, C.; et al. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: Pyroglutamate amyloid beta. *Brain Commun.* **2022**, *4*, fcac022. [[CrossRef](#)]
40. Bakrania, P.; Hall, G.; Bouter, Y.; Bouter, C.; Beindorff, N.; Cowan, R.; Davies, S.; Price, J.; Mpamhanga, C.; Love, E.; et al. Discovery of a novel pseudo beta-hairpin structure of N-truncated amyloid-beta for use as a vaccine against Alzheimer's disease. *Mol. Psychiatry* **2022**, *27*, 840–848. [[CrossRef](#)]
41. Petrushina, I.; Hovakimyan, A.; Harahap-Carrillo, I.S.; Davtyan, H.; Antonyan, T.; Chailyan, G.; Kazarian, K.; Antonenko, M.; Jullienne, A.; Hamer, M.M.; et al. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. *Neurobiol. Dis.* **2020**, *139*, 104823. [[CrossRef](#)]
42. Kim, C.; Hovakimyan, A.; Zagorski, K.; Antonyan, T.; Petrushina, I.; Davtyan, H.; Chailyan, G.; Hasselmann, J.; Iba, M.; Adame, A.; et al. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human alpha-synuclein: Prelude for IND enabling studies. *NPJ Vaccines* **2022**, *7*, 1. [[CrossRef](#)] [[PubMed](#)]
43. Hovakimyan, A.; Antonyan, T.; Shabestari, S.K.; Svystun, O.; Chailyan, G.; Coburn, M.A.; Carlen-Jones, W.; Petrushina, I.; Chadarevian, J.P.; Zagorski, K.; et al. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: Therapeutic efficacy in PS19 mice. *Sci. Rep.* **2019**, *9*, 15455. [[CrossRef](#)]
44. Hovakimyan, A.; Zagorski, K.; Chailyan, G.; Antonyan, T.; Melikyan, L.; Petrushina, I.; Batt, D.G.; King, O.; Ghazaryan, M.; Donthi, A.; et al. Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. *NPJ Vaccines* **2022**, *7*, 117. [[CrossRef](#)] [[PubMed](#)]

45. Davtyan, H.; Ghochikyan, A.; Petrushina, I.; Hovakimyan, A.; Davtyan, A.; Cribbs, D.H.; Agadjanyan, M.G. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. *Alzheimer's Dement.* **2014**, *10*, 271–283. [CrossRef] [PubMed]
46. Davtyan, H.; Hovakimyan, A.; Kiani Shabestari, S.; Antonyan, T.; Coburn, M.A.; Zagorski, K.; Chailyan, G.; Petrushina, I.; Svystun, O.; Danhash, E.; et al. Testing a MultiTEP-based combination vaccine to reduce Abeta and tau pathology in Tau22/5xFAD bigenic mice. *Alzheimer's Res. Ther.* **2019**, *11*, 107. [CrossRef] [PubMed]
47. Neddens, J.; Daurer, M.; Flunkert, S.; Beutl, K.; Loeffler, T.; Walker, L.; Attems, J.; Hutter-Paier, B. Correlation of pyroglutamate amyloid beta and ptau Ser202/Thr205 levels in Alzheimer's disease and related murine models. *PLoS ONE* **2020**, *15*, e0235543. [CrossRef] [PubMed]
48. Eimer, W.A.; Vassar, R. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. *Mol. Neurodegener.* **2013**, *8*, 2. [CrossRef] [PubMed]
49. Wittnam, J.L.; Portelius, E.; Zetterberg, H.; Gustavsson, M.K.; Schilling, S.; Koch, B.; Demuth, H.U.; Blennow, K.; Wirths, O.; Bayer, T.A. Pyroglutamate amyloid beta (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. *J. Biol. Chem.* **2012**, *287*, 8154–8162. [CrossRef]
50. Oakley, H.; Cole, S.L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. *J. Neurosci.* **2006**, *26*, 10129–10140. [CrossRef]
51. Guntert, A.; Dobeli, H.; Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. *Neuroscience* **2006**, *143*, 461–475. [CrossRef]
52. Wang, Y.L.; Tan, M.S.; Yu, J.T.; Zhang, W.; Hu, N.; Wang, H.F.; Jiang, T.; Tan, L. Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer's disease in Han Chinese. *J. Neuroinflammation* **2013**, *10*, 101. [CrossRef] [PubMed]
53. Wang, M.M.; Miao, D.; Cao, X.P.; Tan, L.; Tan, L. Innate immune activation in Alzheimer's disease. *Ann. Transl. Med.* **2018**, *6*, 177. [CrossRef] [PubMed]
54. Selles, M.C.; Fortuna, J.T.S.; Santos, L.E. Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease? *J. Neurosci.* **2017**, *37*, 4864–4867. [CrossRef]
55. Venegas, C.; Heneka, M.T. Danger-associated molecular patterns in Alzheimer's disease. *J. Leukoc. Biol.* **2017**, *101*, 87–98. [CrossRef] [PubMed]
56. Benbenishty, A.; Gadrach, M.; Cottarelli, A.; Lubart, A.; Kain, D.; Amer, M.; Shaashua, L.; Glasner, A.; Erez, N.; Agalliu, D.; et al. Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation. *PLoS Biol.* **2019**, *17*, e2006859. [CrossRef] [PubMed]
57. World Health Organization. Dementia Key Fact. 2021. Available online: <http://www.who.int/mediacentre/factsheets/fs362/en/> (accessed on 15 March 2023).
58. Alzheimer's Association. *Alzheimer's Disease Facts and Figures*; Alzheimer's Association: Chicago, IL, USA, 2023.
59. Panza, F.; Lozupone, M.; Loggrosino, G.; Imbimbo, B.P. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. *Nat. Rev. Neurol.* **2019**, *15*, 73–88. [CrossRef]
60. Maia, M.A.; Sousa, E. BACE-1 and gamma-Secretase as Therapeutic Targets for Alzheimer's Disease. *Pharmaceuticals* **2019**, *12*, 41. [CrossRef]
61. Zhao, J.; Liu, X.; Xia, W.; Zhang, Y.; Wang, C. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. *Front. Mol. Neurosci.* **2020**, *13*, 137. [CrossRef]
62. Tamayev, R.; D'Adamio, L. Inhibition of gamma-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia. *Mol. Neurodegener.* **2012**, *7*, 19. [CrossRef]
63. Panza, F.; Lozupone, M.; Watling, M.; Imbimbo, B.P. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? *Expert Rev. Neurother.* **2019**, *19*, 599–602. [CrossRef]
64. Salloway, S.; Farlow, M.; McDade, E.; Clifford, D.B.; Wang, G.; Llibre-Guerra, J.J.; Hitchcock, J.M.; Mills, S.L.; Santacruz, A.M.; Aschenbrenner, A.J.; et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nat. Med.* **2021**, *27*, 1187–1196. [CrossRef] [PubMed]
65. Puzzo, D.; Arancio, O. Amyloid-beta peptide: Dr. Jekyll or Mr. Hyde? *J. Alzheimer's Dis.* **2013**, *33* (Suppl. S1), S111–S120. [CrossRef]
66. Pearson, H.A.; Peers, C. Physiological roles for amyloid beta peptides. *J. Physiol.* **2006**, *575*, 5–10. [CrossRef] [PubMed]
67. Brothers, H.M.; Gosztyla, M.L.; Robinson, S.R. The Physiological Roles of Amyloid-beta Peptide Hint at New Ways to Treat Alzheimer's Disease. *Front. Aging Neurosci.* **2018**, *10*, 118. [CrossRef] [PubMed]
68. Zagorski, K.; Chailyan, G.; Hovakimyan, A.; Antonyan, T.; Kiani Shabestari, S.; Petrushina, I.; Davtyan, H.; Cribbs, D.H.; Blurton-Jones, M.; Masliah, E.; et al. Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological alpha-Synuclein. *Int. J. Mol. Sci.* **2022**, *23*, 6080. [CrossRef] [PubMed]
69. Oh, S.J.; Lee, J.K.; Shin, O.S. Aging and the Immune System: The Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. *Immune Netw.* **2019**, *19*, e37. [CrossRef]
70. Aran Terol, P.; Kumita, J.R.; Hook, S.C.; Dobson, C.M.; Esbjorner, E.K. Solvent exposure of Tyr10 as a probe of structural differences between monomeric and aggregated forms of the amyloid-beta peptide. *Biochem. Biophys. Res. Commun.* **2015**, *468*, 696–701. [CrossRef]

71. Coles, M.; Bicknell, W.; Watson, A.A.; Fairlie, D.P.; Craik, D.J. Solution structure of amyloid beta-peptide(1–40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? *Biochemistry* **1998**, *37*, 11064–11077. [[CrossRef](#)]
72. Larsen, J.E.; Lund, O.; Nielsen, M. Improved method for predicting linear B-cell epitopes. *Immunome Res.* **2006**, *2*, 2. [[CrossRef](#)]
73. Simpson, R.J. Rapid coomassie blue staining of protein gels. *Cold Spring Harb. Protoc.* **2010**, *2010*, pdb.prot5413. [[CrossRef](#)]
74. Hermanson, G.T. *Bioconjugate Techniques*; Academic Press: Cambridge, MA, USA, 2013.
75. Guo, Y.; Shen, X.N.; Wang, H.F.; Chen, S.D.; Zhang, Y.R.; Chen, S.F.; Cui, M.; Cheng, W.; Dong, Q.; Ma, T.; et al. The dynamics of plasma biomarkers across the Alzheimer’s continuum. *Alzheimer’s Res. Ther.* **2023**, *15*, 31. [[CrossRef](#)]
76. Pereira, J.B.; Janelidze, S.; Stomrud, E.; Palmqvist, S.; van Westen, D.; Dage, J.L.; Mattsson-Carlgrén, N.; Hansson, O. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. *Brain* **2021**, *144*, 2826–2836. [[CrossRef](#)] [[PubMed](#)]
77. Khan, T.K. An Algorithm for Preclinical Diagnosis of Alzheimer’s Disease. *Front. Neurosci.* **2018**, *12*, 275. [[CrossRef](#)] [[PubMed](#)]
78. Barthelemy, N.R.; Li, Y.; Joseph-Mathurin, N.; Gordon, B.A.; Hassenstab, J.; Benzinger, T.L.S.; Buckles, V.; Fagan, A.M.; Perrin, R.J.; Goate, A.M.; et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. *Nat. Med.* **2020**, *26*, 398–407. [[CrossRef](#)] [[PubMed](#)]
79. Teunissen, C.E.; Verberk, I.M.W.; Thijssen, E.H.; Vermunt, L.; Hansson, O.; Zetterberg, H.; van der Flier, W.M.; Mielke, M.M.; Del Campo, M. Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. *Lancet Neurol.* **2022**, *21*, 66–77. [[CrossRef](#)]
80. Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.; Chetelat, G.; Teunissen, C.E.; Cummings, J.; van der Flier, W.M. Alzheimer’s disease. *Lancet* **2021**, *397*, 1577–1590. [[CrossRef](#)]
81. Marttinen, M.; Paananen, J.; Neme, A.; Mitra, V.; Takalo, M.; Natunen, T.; Paldanius, K.M.A.; Makinen, P.; Bremang, M.; Kurki, M.I.; et al. A multiomic approach to characterize the temporal sequence in Alzheimer’s disease-related pathology. *Neurobiol. Dis.* **2019**, *124*, 454–468. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.